乙醇提取物改善酒精诱导的肝损伤通过影响代谢途径
Dae Kyeong Kim1, Priyanka Rajan2, Do Manh Cuong1
1Interdisciplinary Graduate Program in Advanced Convergence Technology and Science, Jeju National University, Jeju 63243, Republic of Korea.
Journal of agricultural and food chemistry
|April 8, 2024
概括
梅洛西拉姆化物乙醇提取物 (MNE) 通过减少有害脂质和炎症,保护肝脏免受酒精引起的损伤. 这种微藻提取物增强脂肪酸代谢和抗氧化剂防御,提供一种潜在的天然治疗策略.
科学领域:
- 生物化学 生化学
- 肝病学 肝病学是一种肝病学.
- 营养保健品 营养保健品
背景情况:
- 酒精诱导的肝损伤 (AILI) 是一个重大的健康问题.
- 微藻类,如Melosira nummuloides,具有有益的脂肪酸特征.
- 研究用于AILI治疗的天然化合物至关重要.
研究的目的:
- 为了研究Melosira nummuloides乙醇提取物 (MNE) 的肝保护作用.
- 阐明MNE在改善酒精引起的肝损伤的潜在机制.
主要方法:
- 给长期饮酒过度的酒小鼠和酒精治疗的HepG2细胞服用MNE.
- 血清标记物的生物化学分析 (TG,T-CHO,AST,ALT).
- 对关键蛋白质 (AMPK,PPARα,SREBP-1,Akt,NFκB,COX-2) 和抗氧化酶 (SOD,NQO1,GPX) 的西部斑分析.
- 脂质代谢物的代谢学分析.
主要成果:
- 在小鼠中,MNE降低了血清甘油三,总胆固醇,AST和ALT水平.
- MNE增加了P-AMPK/AMPK和PPARα,同时降低了SREBP-1,表明抑制了脂肪生成和改善了脂肪酸氧化.
- MNE提高了抗氧化酶 (SOD,NQO1,GPX) 的调节,抑制了Akt/NFκB/COX-2通路,减少了炎症.
- 代谢分析显示HepG2细胞中MNE调节的脂质代谢物.
结论:
- MNE显示出对酒精诱导的肝损伤有显著的肝保护作用.
- 通过抑制脂肪生成,增强脂肪酸氧化,增强抗氧化能力和减少炎症来起作用.
- 对于管理AILI而言,MNE代表了一个有前途的自然治疗剂.
相关概念视频
CNS Depressants: Alcohol and Nicotine
Ethanol, a clear colorless alcohol, has been consumed by humans for millennia, but its effects on the body are far from benign. At lower doses, it induces decreased inhibitions and loquaciousness, leading to its social appeal. However, it can cause severe consequences at higher doses, such as coma and respiratory depression, due to its zero-order elimination kinetics. Chronic ethanol abuse wreaks havoc on multiple organ systems, particularly the CNS and the liver. Abrupt cessation of ethanol...
Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow
Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug binding...
Effect of Hepatic Disease on Pharmacokinetics: Active Drug, Metabolite and Fraction of Metabolized Drug
In pharmacotherapy, monitoring drug concentrations is paramount, especially for drugs whose therapeutic effects hinge on both the active compound and its metabolite. Hepatic impairment profoundly influences drug potency by altering liver function. If the drug is more potent than its metabolite, impaired liver function amplifies drug activity due to elevated drug concentration levels. Conversely, if the metabolite holds greater potency, diminished liver function diminishes drug activity by...
Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test
In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess the...
Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment
Hepatic impairment, characterized by decreased liver function, does not uniformly mandate adjustments in drug dosage. Whether dosage modifications are necessary depends on various factors related to the drug's metabolism and elimination pathways. If a drug is primarily excreted via the kidneys and bypasses significant hepatic processing, if it undergoes minimal metabolic transformation in the liver, or if it is volatile and primarily expelled through the lungs, dose adjustments may not be...
Drug toxicity: Drug–Drug Interaction
Drug–drug interactions can precipitate toxicity through multiple mechanisms. Absorption interactions alter how drugs enter the body, exemplified when ranitidine increases the absorption of basic drugs, while cholestyramine decreases the levels of propranolol. Protein binding interactions occur when drugs share the same binding sites on plasma proteins. Drugs like aspirin and warfarin, when bound in excess, can lead to increased free drug concentrations, enhancing the potential for...


